Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

SEP 30, 2013 - Benzinga

A Must Read - Share

Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec

AMGEN (NASDAQ: AMGN) today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Tags: Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec,  Amgen Latest News